Unichem Laboratories Ltd. — Major Shareholding Notification 2023

Aug 2, 2023

BY E-MAIL

August 2, 2023

BSE Ltd.	The National Stock Exchange of India Ltd.
Phiroze Jeejeebhoy Towers	Exchange Plaza, 5 th Flr, Plot # C/1
27 th Floor, Dalal Street	G Block, Bandra-Kurla Complex,
Mumbai 400 023	Bandra (E), Mumbai 400 051.
E-mail: corp.relations@bseindia.com	E-mail: takeover@nse.co.in

Dear Sir,

Re: Declaration under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Pursuant to Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we are enclosing herewith disclosure for acquisition by us of 2,35,01,440 equity shares of Rs. 2/- each of M/s. Unichem Laboratories Limited (506690 on BSE; UNICHEMLAB on NSE) constituting about 33.38% voting rights of the said Company.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully For and on behalf Ipca Laboratories Limited

Harish P. Kamath Company Secretary

Encl: a/a

Unichem Laboratories Limited Cc: Unichem Bhavan Prabhat Estate, Off S.V.Road, Jogeshwari (West), Mumbai - 400 102 E-mail id: pradeep.bhandari@unichemlabs.com shares@unichemlabs.com

Ipca Laboratories Ltd. www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444 E: ipca@ipca.com CIN: L24239MH1949PLC007837

Format for disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC) Unichem Laboratories Limited (506690 on BSE; UNICHEMLAB on NSE) Name(s) of the acquirer and Persons Acting in Ipca Laboratories Limited Concert (PAC) with the Acquirer No Whether the acquirer belongs to Promoter / Promoter Group Name(s) of the Stock Exchange(s) where the BSE Ltd. (BSE); and shares of TC are listed The National Stock Exchange of India Ltd. (NSE) % w.r.t. total Details of the acquisition as follows Number % w.r.t total share / voting diluted share / capital voting capital of wherever the TC $()$ applicable $(*)$ Before the acquisition under consideration, holding of acquirer along with PACs of: Nil Nil Nil Shares carrying voting rights a. Nil Shares in the nature of encumberance Nil Nil $b.$ (pledge/lien/non-disposal undertaking/others) Nil Nil Nil Voting rights (VR) otherwise than by c. equity shares Nil Warrants / convertible securities / any Nil Nil d. other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) Nil e. Total $(a+b+c+d)$ Nil Nil Details of Acquisition** 33.38% 2,35,01,440 33.38% Shares carrying voting rights acquired a. Nil Nil Nil $_b$ . VRs acquired otherwise than by equity shares Nil Warrants / Convertible securities / any Nil Nil $\mathbf{c}$ . other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired Shares in the nature of encumberance Nil Nil Nil d. (pledge/lien/non-disposal undertaking/others)

Part A - Details of Acquisition

Total $(a+b+c+/-d)$

e.

Ipca Laboratories Ltd.

33.38%

www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444 E: ipca@ipca.com CIN: L24239MH1949PLC007837

2,35,01,440

33.38%

	After the acquisition, holding of
a.	Shares carrying voting rights	2,35,01,440	33.38%	33.38%
b.	VRs otherwise than by equity shares	Nil	Nil	Nil
c.	Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	Nil	Nil
f.	Shares in the nature of encumberance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
d.	Total $(a+b+c+d)$	2,35,01,440	33.38%	33.38%
Mode of acquisition (eg. Open market / public issue/rights issue/preferential allotment/inter- se transfer etc.)		Through Block Deal Mechanism of The National Stock Exchange of India Ltd. (NSE)
	Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Not Applicable
	Date of acquisition of shares or date of receipt of intimation of allotment of shares/VR/warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC	2 nd August, 2023
	Equity share capital/total voting capital of the TC before the said acquisition	7,04,05,750 equity shares of Rs. 2/- each amounting to Rs. 14,08,11,500/-	100%	100%
	Equity share capital /total voting capital of the TC after the said acquisition	7,04,05,750 equity shares of Rs. 2/- each amounting to Rs. 14,08,11,500/-	100%	100%
	Total diluted share/voting capital of the TC after the said acquisition (considering balance outstanding convertible warrants)	7,04,05,750 equity shares of Rs. 2/- each amounting to Rs. 14,08,11,500/-	100%	100%

Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444 E: ipca@ipca.com CIN: L24239MH1949PLC007837

Signature of the acquirer / Authorised Signatory:

For Ipca Laboratories I VQ Harish P. Kamath $\cdot$ Company Secretary

Place: Mumbai

Date: 2^nd August, 2023

Ipca Laboratories Ltd. www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444 E: ipca@ipca.com CIN: L24239MH1949PLC007837